LCTX · Lineage Cell Therapeutics, Inc.
2 customers — 92% of revenue (the year ended December 31, 2025)
“For the year ended December 31, 2025, the Company’s top two customers collectively represented 92% of the Company’s total revenue.”
One customer — 92% of revenue (the year ended December 31, 2024)
“For the year ended December 31, 2024, the Company's top single customer represented 92% of the Company’s total revenue.”
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 6, 2026TL;DR. Lineage reported Q2 net income of $1.5M driven by a non-cash $9.4M gain from warrant liability remeasurement as share price declined, while advancing wholly-owned pipeline assets COR1 into in vivo animal testing and ILT1 to multi-liter scale, and expanding the OpRegen GAlette study to 17 sites. Cash runway was extended one quarter to Q3 2028 at $50.8M.
- + Cash runway extended one quarter to Q3 2028 at $50.8M
- + COR1 program advanced into in vivo animal testing with initial preclinical data expected in 2026
- + ILT1 manufacturing initiative scaled from 0.5L to multi-liter scale
- + OpRegen GAlette study expanded from 6 to 17 clinical sites
- + Positive 3-year OpRegen Phase 1/2a data featuring sustained BCVA gains was showcased at Retinal Therapeutics Innovation Summit 2026
- − Total Q2 revenues declined $1.7M year-over-year to $1.1M due to lower Roche collaboration revenue and prior-year VAC termination
- − Q2 R&D expenses increased $1.7M year-over-year to $4.8M driven by preclinical programs
- − Diluted EPS was a loss of $0.03 despite reported basic net income of $0.01 per share, reflecting dilution from warrants
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LCTX
this stock
Lineage Cell Therapeutics, Inc.
|
$260.49M | -44.5% | +53.2% | — | 11.7% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.1% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -5.9% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +589.1% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LCTX | -4.5% | -14.1% | -41.7% | -3.0% | -44.5% |
| SPY | +1.2% | +0.6% | +11.6% | +1.6% | +13.6% |
| vs SPY | -5.7% | -14.7% | -53.2% | -4.6% | -58.1% |